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doi:10.1016/j.jtcvs.2004.02.037602 The Journal of Thoracic and CardioBackground: Surgical coronary revascularization with cardiopulmonary bypass and
cardioplegia has been associated with reperfusion injury. The serine protease
inhibitor aprotinin has been suggested to reduce reperfusion injury, yet a clinically
relevant study examining regional ischemia under conditions of cardiopulmonary
bypass and cardioplegia has not been performed.
Methods: Pigs were subjected to 30 minutes of regional myocardial ischemia by
distal left anterior descending coronary artery occlusion, followed by 60 minutes of
cardiopulmonary bypass with 45 minutes of cardioplegic arrest and 90 minutes of
post–cardiopulmonary bypass reperfusion. The treatment group (n  6) was ad-
ministered aprotinin systemically (40,000 kallikrein-inhibiting units [KIU]/kg in-
travenous loading dose, 40,000 KIU/kg pump prime, and 10,000 KIU · kg1 · h1
intravenous continuous infusion). Control animals (n  6) received crystalloid
solution. Global and regional myocardial functions were analyzed by the left
ventriculardP/dt and the percentage segment shortening, respectively. Left ven-
tricular infarct size was measured by tetrazolium staining. Tissue myeloperoxidase
activity was measured. Myocardial sections were immunohistochemically stained
for nitrotyrosine. Coronary microvessel function was studied by videomicroscopy.
Results: Myocardial infarct size was decreased with aprotinin treatment (27.0% 
3.5% vs 45.3% 3.0%, aprotinin vs control; P .05). Myocardium from the ischemic
territory showed diminished nitrotyrosine staining in aprotinin-treated animals versus
controls, and this was significant by grade (1.3  0.2 vs 3.2  0.2, aprotinin vs
control; P  .01). In the aprotinin group, coronary microvessel relaxation improved
most in response to the endothelium-dependent agonist adenosine diphosphate
(44.7%  3.2% vs 19.7%  1.7%, aprotinin vs control; P  .01). No significant
improvements in myocardial function were observed with aprotinin treatment.
Conclusions: Aprotinin reduces reperfusion injury after regional ischemia and car-
dioplegic arrest. Protease inhibition may represent a molecular strategy to prevent postop-
erative myocardial injury after surgical revascularization with cardiopulmonary bypass.
As percutaneous coronary interventions have become standardtreatment options for multivessel coronary artery disease, patientsreferred for coronary artery bypass grafting have become a high-er-risk group with more severe coronary disease and preoperativemyocardial dysfunction. Coronary bypass grafts deliver bloodflow to ischemic areas of the myocardium but also result in
regional reperfusion injury, and the use of cardiopulmonary bypass (CPB) with
vascular Surgery ● October 2004
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Pcardioplegic arrest introduces a mechanism of further myo-
cardial injury caused by global reperfusion. Reperfusion
injury is associated with myocardial stunning,1,2 coronary
microvascular dysfunction,3,4 and myocardial damage and
necrosis.5 Cardiac dysfunction due to reperfusion injury
increases the risk of postoperative complications because of
impaired organ perfusion despite successful myocardial re-
vascularization. The serine protease inhibitor aprotinin has
been shown to attenuate the inflammatory response to CPB6
and myocardial reperfusion injury.7 Specifically, aprotinin
has been suggested to reduce reperfusion injury in animal
models of regional ischemia,8-10 isolated heart models of
cardioplegic arrest,11,12 and animal models of cardioplegic
arrest.11,13 Although these studies have described favorable
effects of aprotinin in these experimental models, a clini-
cally relevant model that examines both regional ischemia
and CPB with cardioplegic arrest and that simulates surgical
revascularization in patients has not been used to evaluate
aprotinin therapy. In addition, the role of aprotinin in pre-
venting coronary microvascular dysfunction due to reperfu-
sion injury after regional ischemia and CPB has not been
studied. We hypothesized that aprotinin treatment would
reduce reperfusion injury in a model of regional ischemia,
cardioplegic arrest, and reperfusion. We propose that, in
addition to improvements in myocardial protection and re-
ductions in markers of inflammation and tissue injury, apro-
tinin also prevents dysfunction of the coronary microcircu-
lation, a critical determinant of myocardial perfusion.
Methods
Animals
Animals were housed individually and provided with laboratory
chow and water ad libitum. All experiments were approved by the
Beth Israel Deaconess Medical Center Animal Care and Use
Committee and the Harvard Medical Area Standing Committee on
Animals (Institutional Animal Care and Use Committee) and con-
formed to the US National Institutes of Health guidelines regulat-
ing the care and use of laboratory animals (National Institutes of
Health publication 5377-3; 1996).
Experimental Design
Pigs (30 to 35 kg) were divided randomly into control (n  6) and
aprotinin treatment (n  6) groups. Groups were subjected to
regional left ventricular (LV) ischemia by left anterior descending
coronary artery (LAD) occlusion distal to the first diagonal branch
for 30 minutes before CPB. Animals underwent CPB with car-
dioplegic arrest for 60 minutes. After 5 minutes of CPB, a period
of 45 minutes of hyperkalemic cardioplegic arrest followed. The
aortic crossclamp then was removed and the LAD occlusion re-
leased to reperfuse the myocardium for 10 minutes on CPB, after
which the animal was weaned from CPB. The myocardium was
reperfused for a total of 90 minutes after CPB. The treatment group
received aprotinin systemically (Trasylol; aprotinin injection;
Bayer Pharmaceuticals Corporation, West Haven, Conn) as fol-
lows: a 40,000 kallikrein-inhibiting unit (KIU)/kg intravenous (IV)
The Journal of Thoraciloading dose, a 40,000 KIU/kg CPB circuit prime, and a 10,000
KIU · kg1 · h1 IV continuous infusion. The control group was
administered IV crystalloid solution. Arterial blood gas (ABG),
arterial blood pressure, hematocrit, LV pressure, coronary blood
flow, heart rate, electrocardiogram, oxygen saturation, and tem-
perature were monitored.
Surgical Procedure
Pigs were anesthetized with intramuscular ketamine hydrochloride
(20 mg/kg) and xylazine (15 mg/kg). General anesthesia with
isoflurane gas was maintained by endotracheal intubation and
mechanical ventilation, which was held during CPB. The right
internal jugular vein and carotid artery were cannulated for mon-
itoring. Through a median sternotomy, a catheter-tipped manom-
eter was placed through the LV apex for pressure measurement.
Four 2-mm ultrasonic crystals (Sonometrics Corporation, Ontario,
Canada) were placed in the subepicardial layer of the distal LAD
territory for analysis of regional myocardial function. A 2-mm
ultrasonic coronary flowprobe (Transonic Systems Inc, Ithaca,
NY) was placed distal to the site of LAD occlusion. Pigs were
given IV heparin (300 U/kg) and cannulated via the distal ascend-
ing aorta and right atrium. A vessel loop was passed around the
LAD distal to the first diagonal branch for occlusion. CPB was
initiated with a kaolin-activated clotting time of more than 480
seconds, which was maintained with repeat administrations of IV
heparin. The proximal aorta was crossclamped, and cold crystal-
loid cardioplegia was infused into the aortic root. An initial 300
mL of cold high-potassium cardioplegia (0°C to 4°C; K 25
mmol/L) was administered, followed by 150 mL of cold low-
potassium cardioplegia (0°C to 4°C; K 12 mmol/L), every 15
minutes. The composition of the crystalloid cardioplegic solution
was (mmol/L) NaCl 121, KCl 25 or 12, NaHCO3 12, and glucose
11.
Measurement of Global and Regional Myocardial
Function
Global myocardial function was assessed by calculating the max-
imum positive first derivative of LV pressure over time (dP/dt).
Regional myocardial function was determined by using subepicar-
dial 2-mm ultrasonic probes (Sonometrics Corporation) to calcu-
late the percentage segment shortening (%SS), which was normal-
ized to the baseline.
Coronary Microvessel Studies
Coronary arterioles (60-180 m internal diameter) were dissected
from the LV tissue of the ischemic distal LAD-dependent region.
Microvessel studies were performed by in vitro organ bath video-
microscopy as previously described.14 Endothelium-dependent re-
laxation to adenosine diphosphate (109 to 104 mol/L) and
substance P (1014 to 106 mol/L) and endothelium-independent
relaxation responses to sodium nitroprusside (SNP; 109 to 104
mol/L) were examined.
Myocardial Infarct Size, Nitrotyrosine Staining, and
Myeloperoxidase Activity
At the completion of 90 minutes of post-CPB reperfusion, the LV
ischemic area and infarct size were measured by triphenyl tetra-
15zolium chloride staining as previously described. Nitrotyrosine
c and Cardiovascular Surgery ● Volume 128, Number 4 603
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CSPstaining as a measure of peroxynitrite was performed on myocar-
dial tissue from the distal LAD territory by immunohistochemistry
as previously described.16 All immunohistochemical samples were
graded (0 to 4; 0 indicated no staining, and 4 indicated dark
staining) by a blinded investigator. Myocardial tissue from the
distal LAD territory was harvested, and myeloperoxidase (MPO)
activity was measured as previously described.17 Assessment of
this assay in our laboratory demonstrated a linear relationship (r
0.92) such that 1 U of MPO activity correlated with 2.9  106
porcine neutrophils.
Statistical Analysis
Data are shown as mean  SEM. Statistical analyses were per-
formed with the Mann-Whitney U test and analysis of variance as
appropriate.
Results
Hemodynamic Parameters, ABG, Temperature, and
Hematocrit
No significant differences in heart rate, mean arterial blood
Figure 1. Global and regional myocardial function. The LVdP/dt
was similar in both the control and treatment groups at baseline,
during regional ischemia, and in the period of post-CPB reperfu-
sion (top). Both groups showed dyskinesis of the distal LAD
territory, as seen by negative percentage segment shortening
during regional ischemia and post-CPB reperfusion. Whereas the
impairment in regional function was characterized by increasing
dyskinesis in the control group, aprotinin treatment resulted in a
trend of decreasing dyskinesis, with a significant difference at 90
minutes of post-CPB reperfusion (*P < .05 vs control). BL, Base-
line; 15I, 15 minutes of ischemia; 30I, 30 minutes of ischemia; 30R,
30 minutes of reperfusion; 60R, 60 minutes of reperfusion; 90R, 90
minutes of reperfusion.pressure, ABG parameters, or temperature were observed
604 The Journal of Thoracic and Cardiovascular Surgery ● Octobetween groups. Hematocrit was similar in the control
(21.4%  0.7%) and aprotinin (22.6%  1.0%) groups.
Global and Regional Myocardial Function and
Coronary Blood Flow
No significant differences in the LV dP/dt were observed
between groups (Figure 1, top). In control and aprotinin-
treated animals, regional ischemia resulted in dyskinesis in
the distal LAD territory, resulting in negative %SS (Figure
1, bottom). During post-CPB reperfusion, the regional myo-
cardial function showed trends of increasing dyskinesis in
the control group and decreasing dyskinesis in the aprotinin
group, with a significant difference at 90 minutes of post-
CPB reperfusion (0.08%  0.02% vs 1.05%  0.3%
SS, aprotinin vs control, respectively; P  .05). No signif-
icant differences were observed between groups in coronary
blood flow (Figure 2).
Myocardial Infarct Size, Nitrotyrosine Staining, and
MPO Activity
The myocardial infarct size, measured as a percentage of the
ischemic area, was significantly reduced in the aprotinin
group compared with controls (27.0%  3.5% vs 45.3% 
3.0%, aprotinin vs control, respectively; P  .05; Figures 3
and 4). Myocardial sections stained for nitrotyrosine as a
measure of peroxynitrite showed reduced staining by grade
in the aprotinin group compared with controls (1.3  0.2 vs
3.2  0.2, aprotinin vs control, respectively; P  .01;
Figure 5). MPO activity as a measure of neutrophil infiltra-
tion was decreased in myocardial tissue from aprotinin-
treated animals compared with control animals (0.09 0.03
U/mg of tissue vs 0.26  0.07 U/mg of tissue, aprotinin vs
control, respectively; P  .05; Figure 6).
Coronary Microvascular Function
Aprotinin treatment produced increased relaxation re-
sponses of coronary arterioles to the endothelium-dependent
Figure 2. Coronary blood flow. No significant differences were
observed in coronary blood flow between groups. BL, Baseline;
15I, 15 minutes of ischemia; 30I, 30 minutes of ischemia; 30R, 30
minutes of reperfusion; 60R, 60 minutes of reperfusion; 90R, 90
minutes of reperfusion.agonists adenosine diphosphate and substance P compared
ber 2004
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Pwith controls (Figure 7, top and middle, respectively). The
relaxation responses to the endothelium-independent ago-
nist SNP were also increased in the aprotinin group com-
pared with controls (Figure 7, bottom).
Discussion
The principal findings of the study are that in a porcine
model of regional myocardial ischemia and cardioplegic
arrest followed by reperfusion, aprotinin treatment has the
following effects: (1) reduction of myocardial infarct size,
(2) prevention of neutrophil accumulation and peroxynitrite
generation, and (3) enhancement of coronary microvascular
relaxation. An important aspect of this study is that the
beneficial effects of aprotinin were observed after both
regional ischemia of the LAD territory and global ischemia
with cardioplegic arrest. Our results in this clinically rele-
vant model suggest that patients undergoing coronary artery
bypass grafting with CPB and cardioplegic arrest for unsta-
ble angina may similarly benefit from an adjunctive therapy
of serine protease inhibition to prevent myocardial reperfu-
sion injury.
In our study, aprotinin treatment produced a reduction in
myocardial infarct size as less of the ischemic LAD territory
progressed to infarction. A previous study of coronary oc-
clusion in a dog model showed decreased myocardial ne-
crosis with aprotinin,18 yet another study of regional myo-
cardial ischemia in sheep suggested that aprotinin therapy
resulted in increased myocardial damage.19 Although these
results from animal models are inconsistent, several other
studies have provided evidence that aprotinin reduces car-
diac enzyme release due to reperfusion injury. Both in a rat
model of regional ischemia and an isolated, perfused heart
model of cardioplegic arrest, aprotinin treatment resulted in
a decreased release of creatine kinase.10,12 Furthermore, in
patients, aprotinin therapy has been associated with lower
levels of cardiac troponins after cardiac surgery.20,21
Neutrophils play a critical role in reperfusion injury
through a process of adhering to the vascular endothelium,
transmigrating, and accumulating in the reperfused tissue.
During this course, neutrophils are activated and release
cytotoxic metabolites, proteolytic enzymes, and cytokines,
leading to tissue injury and to recruitment of more neutro-
phils. In this study, in the aprotinin group, we observed an
attenuation of neutrophil infiltration by decreased MPO
activity in myocardial tissue from the reperfused LAD ter-
ritory. Aprotinin has been shown to reduce neutrophil ex-
travasation indirectly by measuring MPO activity10 and
directly through intravital microscopy.22 Furthermore, we
observed that aprotinin treatment resulted in decreased ni-
trotyrosine staining of myocardial tissue sections from the
ischemic LAD territory. Tissue nitrotyrosine is a metabolic
product and an indirect measure of peroxynitrite, a nitrogen
radical that is produced during reperfusion injury along with
The Journal of Thoracioxygen radicals. Peroxynitrite is produced in patients during
cardiac operations23 and has been suggested to contribute to
reperfusion injury. In a previous study from our laboratory,
treatment with FP-15, a peroxynitrite inhibitor, decreased
the extent of reperfusion injury in a pig model of regional
myocardial ischemia.16 In addition to reducing nitrogen
radical production, aprotinin has been shown to prevent
oxygen radical formation.24 On the basis of these observa-
tions, mechanisms by which aprotinin attenuates reperfu-
sion injury likely include prevention of neutrophil extrava-
sation and production of oxygen and nitrogen radicals.
Finally, aprotinin therapy was associated with improved
coronary microvascular relaxation, which was impaired be-
cause of reperfusion injury.3,4 In our study, aprotinin en-
Figure 3. Representative image of LV infarct size. Triphenyl tet-
razolium chloride staining was used to determine the LV infarct
size (arrows), which was markedly decreased in the LV myocar-
dium of aprotinin-treated animals (right) compared with controls
(left).
Figure 4. Quantification of LV infarct size. Infarct size was mea-
sured as a percentage of the LV ischemic area. The percent of the
LV ischemic area that progressed to infarction was significantly
reduced in the aprotinin group compared with the LV myocardium
from control animals (*P < .05).hanced relaxation responses to both endothelium-dependent
c and Cardiovascular Surgery ● Volume 128, Number 4 605
Cardiopulmonary Support and Physiology Khan et al
CSP(adenosine diphosphate and substance P) and endothelium-
independent (SNP) agonists. Although evidence suggests
that aprotinin increases endothelium-dependent relaxation
to acetylcholine after hypothermic circulatory arrest,25 the
results of our study did not differentiate between endothe-
lium-dependent and endothelium-independent mechanisms
of coronary vascular smooth muscle relaxation. The mech-
anism by which aprotinin improves coronary microvascular
relaxation after reperfusion injury likely involves the atten-
uation of neutrophil activity.26
A limitation of the study is that crystalloid cardioplegia
was used. Blood cardioplegia has been associated with
greater myocardial protection in laboratory experi-
ments,27,28 and clinical studies have suggested that blood
cardioplegia, compared with crystalloid cardioplegia, may
improve outcomes in patients with severe preoperative
myocardial dysfunction.29,30 Although blood cardioplegia
was not used in our study, there is evidence that aprotinin
Figure 5. Myocardial nitrotyrosine staining. Aprotinin t
tissue peroxynitrite, as shown in the representative my
treated (right) and control (left) animals.
Figure 6. Tissue MPO activity. Tissue MPO activity was deter-
mined as a measure of neutrophil infiltration. Myocardium from
the distal LAD territory had reduced MPO activity with aprotinin
therapy compared with controls (*P < .05).prevents myocardial injury, as measured by troponin re-
606 The Journal of Thoracic and Cardiovascular Surgery ● Octolease, similarly in patients who undergo cardioplegic arrest
with blood or crystalloid solutions.21 Another limitation of
the study is that although aprotinin treatment reduced myo-
cardial infarction and enhanced coronary microvascular re-
laxation, improvement in global and regional myocardial
function was not shown. Although during post-CPB reper-
fusion, aprotinin treatment attenuated the dyskinesis in the
reperfused LAD territory, the resulting akinesis would be
unlikely to provide a significant improvement in regional
myocardial function. A possible explanation for these re-
sults is that after 30 minutes of regional ischemia and 45
minutes of cardioplegic arrest, the stunned myocardium was
still in the recovery phase, which may require 48 hours or
longer after such periods of ischemia for significant resto-
ration of myocardial function.1,2 Overall, although no func-
tional improvement was shown with aprotinin treatment, the
trend of a progressive decrease in dyskinesis during the
post-CPB reperfusion period suggests that aprotinin reduces
the deleterious effects of reperfusion injury on regional LV
function.
In conclusion, the results of our study show that aprotinin
reduces reperfusion injury in a pig model of regional isch-
emia and cardioplegic arrest, as seen by decreased infarct
size, prevention of neutrophil tissue infiltration and nitrogen
radical production, and increased coronary microvascular
relaxation. Although the use of aprotinin may not translate
into a clinically significant benefit in routine patients who
are surgically revascularized, high-risk patients—such as
those with severe coronary artery disease, preoperative car-
diac dysfunction, and diabetes mellitus—may be the popu-
lation that will have greater potential gain from the cardio-
protective effects of serine protease inhibition. As the
current trend of aggressive coronary artery disease manage-
ment by percutaneous coronary intervention results in in-
ent decreased staining for nitrotyrosine, a measure of
dial sections from the distal LAD territory of aprotinin-reatm
ocarcreasingly high-risk patients referred for cardiac surgery,
ber 2004
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Ptherapy such as serine protease inhibition with aprotinin
may allow for continued successful outcomes as cardiac
surgeons are presented with more challenging cases for
coronary revascularization.
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